Cargando…

Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China

BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was used. EMM recorded each time the device was opened (no real time data), offering an indirect measure of tuberculosis treatment adherence. Previous study in China showed that the EMM uptake was satisfactory, missi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ni, Shewade, Hemant Deepak, Thekkur, Pruthu, Zhang, Hui, Yuan, Yanli, Wang, Xiaomeng, Wang, Xiaolin, Sun, Miaomiao, Huang, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652336/
https://www.ncbi.nlm.nih.gov/pubmed/33166361
http://dx.doi.org/10.1371/journal.pone.0242112
_version_ 1783607691878334464
author Wang, Ni
Shewade, Hemant Deepak
Thekkur, Pruthu
Zhang, Hui
Yuan, Yanli
Wang, Xiaomeng
Wang, Xiaolin
Sun, Miaomiao
Huang, Fei
author_facet Wang, Ni
Shewade, Hemant Deepak
Thekkur, Pruthu
Zhang, Hui
Yuan, Yanli
Wang, Xiaomeng
Wang, Xiaolin
Sun, Miaomiao
Huang, Fei
author_sort Wang, Ni
collection PubMed
description BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was used. EMM recorded each time the device was opened (no real time data), offering an indirect measure of tuberculosis treatment adherence. Previous study in China showed that the EMM uptake was satisfactory, missing adherence data were common in the information management system (25%) and shift to directly observed therapy (DOT) based on poor adherence documented by EMMs were seldom. OBJECTIVES: Among people with tuberculosis notified in 30 counties (July-December 2018) where EMM supported self-administered therapy (SAT) was suggested to all eligible (no communication impairment, ambulatory), we assessed the relative differences in unfavourable outcomes and deaths among those started on EMM at baseline (within first month of diagnosis) when compared to SAT alone. METHODS: This was a cohort study using secondary data. We employed an intention to treat analysis, and used modified Poisson regression with robust variance estimates to assess the association. RESULTS: Of 1810 eligible people, 1047 used EMM at baseline and of them, 216 (20.1%) stopped using EMM midway. Of 763 people who did not use EMM at baseline, 267 (35.0%) started using EMM later during the treatment. Among those who started using EMM at baseline, 6.3% [95% CI: 4.9, 8.0] had unfavourable outcomes compared to 6.7% [95% CI: 5.1, 8.8] among those who did not (p = 0.746). Lesser deaths were observed in people who started EMM at baseline when compared to those who did not: 2.5% [95% CI: 1.7, 3.7] versus 3.5% [95% CI: 2.4, 5.2], p = 0.191. The lack of association remained after adjusting for potential confounders (occupation, TB classification and TB category). CONCLUSION: Under programmatic settings, we did not find significant differences in the outcomes. Optimization of EMMs by shifting to DOT when indicated, addressing the issue of missing data and ensuring continuous use is required.
format Online
Article
Text
id pubmed-7652336
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76523362020-11-18 Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China Wang, Ni Shewade, Hemant Deepak Thekkur, Pruthu Zhang, Hui Yuan, Yanli Wang, Xiaomeng Wang, Xiaolin Sun, Miaomiao Huang, Fei PLoS One Research Article BACKGROUND: In China, an indigenously developed electronic medication monitor (EMM) was used. EMM recorded each time the device was opened (no real time data), offering an indirect measure of tuberculosis treatment adherence. Previous study in China showed that the EMM uptake was satisfactory, missing adherence data were common in the information management system (25%) and shift to directly observed therapy (DOT) based on poor adherence documented by EMMs were seldom. OBJECTIVES: Among people with tuberculosis notified in 30 counties (July-December 2018) where EMM supported self-administered therapy (SAT) was suggested to all eligible (no communication impairment, ambulatory), we assessed the relative differences in unfavourable outcomes and deaths among those started on EMM at baseline (within first month of diagnosis) when compared to SAT alone. METHODS: This was a cohort study using secondary data. We employed an intention to treat analysis, and used modified Poisson regression with robust variance estimates to assess the association. RESULTS: Of 1810 eligible people, 1047 used EMM at baseline and of them, 216 (20.1%) stopped using EMM midway. Of 763 people who did not use EMM at baseline, 267 (35.0%) started using EMM later during the treatment. Among those who started using EMM at baseline, 6.3% [95% CI: 4.9, 8.0] had unfavourable outcomes compared to 6.7% [95% CI: 5.1, 8.8] among those who did not (p = 0.746). Lesser deaths were observed in people who started EMM at baseline when compared to those who did not: 2.5% [95% CI: 1.7, 3.7] versus 3.5% [95% CI: 2.4, 5.2], p = 0.191. The lack of association remained after adjusting for potential confounders (occupation, TB classification and TB category). CONCLUSION: Under programmatic settings, we did not find significant differences in the outcomes. Optimization of EMMs by shifting to DOT when indicated, addressing the issue of missing data and ensuring continuous use is required. Public Library of Science 2020-11-09 /pmc/articles/PMC7652336/ /pubmed/33166361 http://dx.doi.org/10.1371/journal.pone.0242112 Text en © 2020 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wang, Ni
Shewade, Hemant Deepak
Thekkur, Pruthu
Zhang, Hui
Yuan, Yanli
Wang, Xiaomeng
Wang, Xiaolin
Sun, Miaomiao
Huang, Fei
Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
title Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
title_full Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
title_fullStr Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
title_full_unstemmed Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
title_short Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China
title_sort do electronic medication monitors improve tuberculosis treatment outcomes? programmatic experience from china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652336/
https://www.ncbi.nlm.nih.gov/pubmed/33166361
http://dx.doi.org/10.1371/journal.pone.0242112
work_keys_str_mv AT wangni doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT shewadehemantdeepak doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT thekkurpruthu doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT zhanghui doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT yuanyanli doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT wangxiaomeng doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT wangxiaolin doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT sunmiaomiao doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina
AT huangfei doelectronicmedicationmonitorsimprovetuberculosistreatmentoutcomesprogrammaticexperiencefromchina